LON:C4XD

C4X Discovery (C4XD) Share Forecast, Price & News

GBX 18.50

+0.90 (+5.11%)

(As of 02:38 PM ET)

Compare

Today's Range: 17.80
▼
18.75
50-Day Range: 13.86
▼
17.60
52-Week Range: 13.60
▼
31

Volume: 350,957 shs
Average Volume: 218,337 shs
Market Capitalization: £46.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Insider Trades Headlines

About C4X Discovery (LON:C4XD) Stock

C4X Discovery Holdings plc operates as drug discovery company in the United Kingdom. The company provides Taxonomy3, a novel in silico platform technology that utilizes proprietary mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behavior and physical properties of drug molecules; and 4Sight for visualizing 4D molecules in virtual reality research scientists to view, understand and interrogate the complex, multidimensional molecular shape data of drug molecules. Its product pipeline includes Orexin-1, a receptor antagonist for the treatment of addictive disorders; NRF-2 activator to treat various inflammatory diseases; IL-17A inhibitor for inflammation and autoimmune diseases; a4ß7 integrin inhibitors for the treatment of inflammatory bowel disease; and MALT-1 inhibitors to treat hematological cancer. It has partnerships with Sanofi, therapeutics, horizon, LifeArc, INDIVIOR, and Phoremost. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. The company was incorporated in 2007 and is based in Manchester, the United Kingdom.

Receive C4XD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for C4X Discovery and its competitors with MarketBeat's FREE daily newsletter.

C4XD Stock News Headlines

June 8, 2023 | finance.yahoo.com

Is C4X Discovery Holdings (LON:C4XD) In A Good Position To Invest In Growth?

June 1, 2023 | lse.co.uk

C4X says MALT-1 study shows no UGT1A1 liability seen in competitors

June 9, 2023 | Edge On The Street (Ad)

Soaring EV Industry Keeps Investor Focus on Lithium

The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.

May 28, 2023 | americanbankingnews.com

C4X Discovery (LON:C4XD) Stock Price Passes Above 50-Day Moving Average of $15.31

May 6, 2023 | americanbankingnews.com

C4X Discovery (LON:C4XD) Stock Price Crosses Above 50-Day Moving Average of $15.13

April 28, 2023 | finance.yahoo.com

C4X Discovery Holdings First Half 2023 Earnings: UK£0.015 loss per share (vs UK£0.02 loss in 1H 2022)

April 26, 2023 | finance.yahoo.com

C4X Discovery Holdings PLC Announces Half Year Results

April 26, 2023 | finance.yahoo.com

C4X Discovery Holdings plc: Half-year results for the six months ended 31 January 2023

June 9, 2023 | Edge On The Street (Ad)

Graphite versus Lithium - What Investors Should Know

Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.

April 13, 2023 | barrons.com

Warner Bros. Discovery Stock Will Climb on DC Superhero Films: Analyst

February 22, 2023 | finance.yahoo.com

C4XD and Garvan Institute of Medical Research report successful patient stratification approach using C4XD's new precision medicine platform PatientSeek

February 19, 2023 | uk.finance.yahoo.com

C4X Discovery Holdings plc (C4XD.L)

January 15, 2023 | reuters.com

C4XD.L - | Stock Price & Latest News | Reuters

November 28, 2022 | msn.com

Drug developer C4X shares fly after signing £330m AstraZeneca licensing deal

November 28, 2022 | msn.com

Shares surge in drug discovery company after $402m AstraZeneca deal announced

November 28, 2022 | reuters.com

UK's C4X Discovery signs $400 mln licensing deal with AstraZeneca

November 28, 2022 | finance.yahoo.com

C4XD Agreement with AstraZeneca

November 28, 2022 | finance.yahoo.com

C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme

October 10, 2022 | bbc.com

The controversy over an incredible archaeological discovery

October 10, 2022 | finance.yahoo.com

We Think C4X Discovery Holdings (LON:C4XD) Can Afford To Drive Business Growth

August 13, 2022 | proactiveinvestors.com.au

C4X Discovery raises £5.7mln from institutional investors

August 11, 2022 | marketwatch.com

C4X Discovery to Raise Up to GBP5.7 Mln to Fund Future Opportunities

July 6, 2022 | finance.yahoo.com

C4X Discovery receives Sanofi milestone payment

June 16, 2022 | finance.yahoo.com

Shareholders in C4X Discovery Holdings (LON:C4XD) are in the red if they invested five years ago

May 2, 2022 | finance.yahoo.com

Companies Like C4X Discovery Holdings (LON:C4XD) Are In A Position To Invest In Growth

April 28, 2022 | proactiveinvestors.com.au

C4X Discovery in advanced discussions to out-license third drug programme

February 14, 2022 | finance.yahoo.com

What Is The Ownership Structure Like For C4X Discovery Holdings plc (LON:C4XD)?

See More Headlines

C4XD Price History

30 days | 90 days | 365 days | Advanced Chart

C4XD Company Calendar

Last Earnings: 4/29/2020
Today: 6/09/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:C4XD
CUSIP: N/A
CIK: N/A
Web: www.c4xdiscovery.com
Phone: +44-161-2355085
Fax: N/A
Employees: 46
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-7,520,000.00
Net Margins: -174.57%
Pretax Margin: N/A
Return on Equity: -52.34%
Return on Assets: -38.99%

Debt

Debt-to-Equity Ratio: 4.33
Current Ratio: 7.24
Quick Ratio: 9.82

Sales & Book Value

Annual Sales: £4.31 million
Price / Sales: 10.30
Cash Flow: GBX 4.40 per share
Price / Cash Flow: 4.00
Book Value: GBX 5 per share
Price / Book: 3.52

Miscellaneous

Outstanding Shares: 252,120,000
Free Float: N/A
Market Cap: £44.37 million
Optionable: Not Optionable
Beta: 0.44

Key Executives

Dr. Clive James Dix B.Sc. (Age 68)
Ph.D., CEO & Exec. Director
Comp: $187k

Mr. Bradley Richard Hoy (Age 60)
CFO, Sec. & Exec. Director
Comp: $203k

Ms. Bhavna Hunjan (Age 37)
Chief Bus. Officer & Exec. Director
Comp: $122k

Ms. Emma Blaney Ph.D.
Chief Operating Officer

Mr. Charles Douglas Blundell DPhil (Age 46)
Chief Technical Officer

Dr. Nick Ray Ph.D.
Sr. VP of Drug Discovery

Dr. Clare Murray Ph.D.
Sr. VP of Drug Discovery

Key Competitors

View All Competitors

C4XD Stock - Frequently Asked Questions

How have C4XD shares performed in 2023?: C4X Discovery's stock was trading at GBX 18 at the start of the year. Since then, C4XD shares have decreased by 2.2% and is now trading at GBX 17.60.
View the best growth stocks for 2023 here.
How were C4X Discovery's earnings last quarter?: C4X Discovery Holdings plc (LON:C4XD) announced its quarterly earnings results on Wednesday, April, 29th. The company reported ($5.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($5.50) by $0.48. C4X Discovery had a negative trailing twelve-month return on equity of 52.34% and a negative net margin of 174.57%.
What other stocks do shareholders of C4X Discovery own?: Based on aggregate information from My MarketBeat watchlists, some companies that other C4X Discovery investors own include Rio Tinto Group (RIO), Ryder System (R), Pearson (PSON), Moss Bros Group (MOSB), Inland Homes (INL), Fundsmith Emerging Equities Trust (FEET), easyJet (EZJ), Card Factory (CARD) and The Berkeley Group (BKG).
What is C4X Discovery's stock symbol?: C4X Discovery trades on the London Stock Exchange (LON) under the ticker symbol "C4XD."

How do I buy shares of C4X Discovery?: Shares of C4XD stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is C4X Discovery's stock price today?: One share of C4XD stock can currently be purchased for approximately GBX 17.60.
How much money does C4X Discovery make?: C4X Discovery (LON:C4XD) has a market capitalization of £44.37 million and generates £4.31 million in revenue each year. The company earns £-7,520,000.00 in net income (profit) each year or GBX (0.03) on an earnings per share basis.
How can I contact C4X Discovery?: C4X Discovery's mailing address is 53 Portland Street, MANCHESTER, M1 3LD, United Kingdom. The official website for the company is www.c4xdiscovery.com. The company can be reached via phone at +44-161-2355085.

This page (LON:C4XD) was last updated on 6/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial